2020
DOI: 10.1186/s13037-020-00245-7
|View full text |Cite
|
Sign up to set email alerts
|

Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report

Abstract: Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease. Case presentati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(12 citation statements)
references
References 35 publications
0
12
0
Order By: Relevance
“…2 In up to 98% of nonsurvivors from COVID-19, high mortality was associated with severe respiratory failure from viral pneumonia. 3,4 The conventional management of patients with ARDS requiring invasive mechanical ventilation includes lung-protective ventilation with low tidal volume, high PEEP, deep sedation, prone positioning, neuromuscular blockade with the use of paralytics, steroids, and inhaled nitric oxide or epoprostenol. 5,6 Although robust evidence in support of benefit with the use of ECMO for ARDS is lacking, it serves as a rescue therapy with a mortality benefit in patients with severe reversible acute respiratory failure when the conventional therapies have failed.…”
Section: Discussionmentioning
confidence: 99%
“…2 In up to 98% of nonsurvivors from COVID-19, high mortality was associated with severe respiratory failure from viral pneumonia. 3,4 The conventional management of patients with ARDS requiring invasive mechanical ventilation includes lung-protective ventilation with low tidal volume, high PEEP, deep sedation, prone positioning, neuromuscular blockade with the use of paralytics, steroids, and inhaled nitric oxide or epoprostenol. 5,6 Although robust evidence in support of benefit with the use of ECMO for ARDS is lacking, it serves as a rescue therapy with a mortality benefit in patients with severe reversible acute respiratory failure when the conventional therapies have failed.…”
Section: Discussionmentioning
confidence: 99%
“…We ultimately included nine studies, 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 seven of which were case reports. 14 , 15 , 16 , 17 , 18 , 19 , 21 Only two studies had more than one patient; an observational design analyzing the clinical course of 19 patients, 20 and a case series of three patients. 13 …”
Section: Methodsmentioning
confidence: 99%
“…The number of total ICU days was 1307 (IQR, 7-11) in Hokkaido, 168 (0-3) days in Tohoku, 9741 (40-127) days in Kanto-Koshinetsu, 1044 (6)(7)(8)(9)(10)(11)(12)(13)(14) days in Tokai-Hokuriku, 4227 (8-65) days in Kansai, 302 (0-5) days in Chugoku-Shikoku, and 1179 (0-20) days in Kyusyu-Okinawa ( Fig. 3 and Fig.…”
Section: Covidmentioning
confidence: 99%
“…Although approximately 70-80% of patients with COVID-19 have mild to moderate symptoms and recover, 5-20% of patients develop severe respiratory failure and may require admission to an intensive care unit (ICU) [3][4][5]. Symptomatic treatment for severe respiratory failure has involved the use of mechanical ventilation and extracorporeal membrane oxygenation (ECMO) [5][6][7][8][9] as there are currently no speci c drugs or other procedures available to treat patients with COVID-19. One study that analyzed clinical cases of COVID-19 reported a better prognosis in patients with mild infection, whereas the prognosis for patients with severe and critical infections is poor.…”
Section: Introductionmentioning
confidence: 99%